NZ744238B2 - Fermented formula with non-digestible oligosaccharides - Google Patents
Fermented formula with non-digestible oligosaccharidesInfo
- Publication number
- NZ744238B2 NZ744238B2 NZ744238A NZ74423816A NZ744238B2 NZ 744238 B2 NZ744238 B2 NZ 744238B2 NZ 744238 A NZ744238 A NZ 744238A NZ 74423816 A NZ74423816 A NZ 74423816A NZ 744238 B2 NZ744238 B2 NZ 744238B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- oligosaccharide
- nutritional composition
- lactic acid
- use according
- fermented
- Prior art date
Links
Abstract
fermented formula comprising non digestible oligosaccharides synergistically stimulates secretory IgA in infants. In particular, the invention provides the use of a composition comprising 0.02-1.5 wt% lactic acid bacteria and lactate combined, produced from a fermented lactic acid bacteria and 2.5-15 wt% non-digestible oligosaccharides to increase IgA secretion and improve mucosal immune defense in infants or babies.
Claims (13)
1. Use of a fermented ingredient and gestible oligosaccharide in the manufacture of a nutritional composition for preventing or treating a disorder that is prevented or treated by increasing IgA secretion in a human subject with an age of 0 to 36 months, wherein the fermented ingredient is a composition that is fermented by lactic acid producing bacteria and wherein the ional composition comprises 0.02 to 1.5 wt% of the sum of lactic acid and lactate based on dry weight of the nutritional composition and comprises 2.5 to 15 wt% non-digestible oligosaccharide based on dry weight of the nutritional composition.
2. Use of a fermented ingredient and non-digestible oligosaccharide in the manufacture of a nutritional composition for use in improving l immune defense in a human subject with an age of 0 to 36 months, wherein the fermented ingredient is a ition that is ted by lactic acid producing bacteria and wherein the nutritional composition comprises 0.02 to 1.5 wt% of the sum of lactic acid and lactate based on dry weight of the nutritional composition and comprises 2.5 to 15 wt% nondigestible oligosaccharide based on dry weight of the nutritional composition.
3. The use according to any one of the preceding claims wherein the fermented ingredient is a milk substrate that is fermented by lactic acid producing bacteria, and said milk ate comprises at least one selected from the group consisting of milk, whey, whey protein, whey protein hydrolysate, casein, casein hydrolysate, and lactose or mixtures thereof.
4. The use ing to any one of the preceding claims, wherein the nutritional composition is an infant formula, a follow on formula or a g up milk.
5. The use according to any one of the preceding claims, wherein the gestible oligosaccharide is selected from the group consisting of fructo-oligosaccharide, non- digestible dextrin, galacto-oligosaccharide, xylo-oligosaccharide, arabinooligosaccharide , ogalacto-oligosaccharide, gluco-oligosaccharide, gentiooligosaccharide , glucomanno-oligosaccharide, galactomanno-oligosaccharide, mannan-oligosaccharide, isomalto-oligosaccharide, nigero-oligosaccharide, glucomanno-oligosaccharide, chito-oligosaccharide, soy oligosaccharide, uronic acid oligosaccharide, sialyloligosaccharide, and fuco-oligosaccharide, and mixtures thereof.
6. The use ing to any one of the preceding , wherein the non-digestible oligosaccharide comprises galacto-oligosaccharide and/or fructo-oligosaccharide.
7. The use according to any one of the preceding claims, wherein at least 90 wt% of the sum of lactic acid and lactate is L(+)-lactic acid and/or L(+)-lactate.
8. The use according to any one of the preceding claims, wherein the fermented ingredient is fermented by Bifidobacterium and/or ococcus.
9. The use according to any one of the preceding claims n the nutritional composition comprises Bifidobacterium breve and/or ococcus thermophilus.
10. The use according to any one of the preceding claims wherein the lactic acid producing bacteria are inactivated to a level below 105, more preferably below 103 cfu/g dry weight of the nutritional composition.
11. The use according to any one of the preceding claims wherein the nutritional composition comprises protein, digestible carbohydrate and lipid and wherein the protein provides 1.6 to 4 g per 100 kcal, the digestible carbohydrates provides 5 to 20 g per 100 kcal and the lipid es 3 to 7 g lipid per 100 kcal of the nutritional composition.
12. Use according to claim 1, substantially as herein described or ified.
13. Use according to claim 2, substantially as herein described or exemplified.
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NZ744238A NZ744238A (en) | 2025-01-31 |
| NZ744238B2 true NZ744238B2 (en) | 2025-05-01 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Walton et al. | Mechanisms linking the human gut microbiome to prophylactic and treatment strategies for COVID-19 | |
| CN102123715B (en) | Nutrients that Stimulate the Immune System | |
| Jeurink et al. | Mechanisms underlying immune effects of dietary oligosaccharides | |
| CN101400267B (en) | Oligosaccharide mixture | |
| US11998030B2 (en) | Non-dairy drink with rice and pea proteins | |
| US9005682B2 (en) | Synbiotic mixture | |
| Lara-Villoslada et al. | Beneficial effects of probiotic bacteria isolated from breast milk | |
| AU2012260945B2 (en) | Milk oligosaccharide-galactooligosaccharide composition for infant formula containing the soluble oligosaccharide fraction present in milk, and having a low level of monosaccharides, and a process to produce the composition | |
| RU2015100867A (en) | ACID-MILK MIXTURE FOR BREAST CHILDREN WITH UNDIGABLE OLIGOSACCHARIDES | |
| US9498502B2 (en) | Prevention and treatment of allergic diarrhea | |
| RU2018127650A (en) | Fermented milk mixture with indigestible oligosaccharides | |
| CN118632706A (en) | Compositions comprising osteopontin (OPN) | |
| NZ744238B2 (en) | Fermented formula with non-digestible oligosaccharides | |
| NZ744238A (en) | Fermented formula with non-digestible oligosaccharides | |
| US20160206658A1 (en) | Nutrition for prevention of infections | |
| Bengmark | Synbiotics in human Medicine | |
| RU2833704C2 (en) | Use of non-dairy beverage with rice and pea proteins for feeding babies with cow protein allergy | |
| HK1261683A1 (en) | Fortified milk-based nutritional compositions |